Senti Biosciences, Inc. 8-K

What Happened

• Senti Biosciences, Inc. (SNTI) announced its financial results for the year ended December 31, 2025 via a press release dated March 27, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8-K filed the same day. The Form 8-K was signed by CEO Timothy Lu, M.D., Ph.D.

Key Details

• Event: Press release announcing year-end 2025 financial results issued March 27, 2026.
• Reporting period: Results cover the year ended December 31, 2025.
• Filing: Information furnished on Form 8-K under Item 2.02 (Results of Operations and Financial Condition); press release attached as Exhibit 99.1.
• Authorized signature: Form 8-K signed by Timothy Lu, Chief Executive Officer and President, dated March 27, 2026.

Why It Matters

• This 8-K signals Senti has publicly reported its annual earnings/financial condition for 2025; investors should read the furnished press release (Exhibit 99.1) for revenue, net income/loss, cash position, and any management commentary or guidance.
• Because the 8-K furnishes the press release rather than embedding detailed financial tables in the filing text, retail investors should review the exhibit to assess impacts on valuation, cash runway, and near-term milestones.